Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study

- Cuzick, Jack, Warwick, Jane, Pinney, Elizabeth, Duffy, Stephen W., Cawthorn, Simon, Howell, Anthony, Forbes, John F., Warren, Ruth M. L.

HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2

- Bartlett, John M. S., Ahmed, Ikhlaaq, Brookes, Cassandra L., Forbes, John F., Viale, Giuseppe, Cuzick, Jack, Dowsett, Mitchell, Rea, Daniel W., Regan, Meredith M., Sestak, Ivana, Mallon, Elizabeth A., Dell'Orto, Patrizia, Thürlimann, Beat, Seynaeve, Caroline, Putter, Hein, Van de Velde, Cornelis J. H.

Preventive therapy for breast cancer: a consensus statement

- Cuzick, Jack, DeCensi, Andrea, Vogel, Victor, Zwierzina, Heinz, Arun, Banu, Brown, Powell H., Castiglione, Monica, Dunn, Barbara, Forbes, John F., Glaus, Agnes, Howell, Anthony, Von Minckwitz , Gunter

Influence of comorbidities and age on risk of death without recurrence: a retrospective analysis of the arimidex, tamoxifen alone or in combination trial

- Ring, Alistair, Sestak, Ivana, Baum, Michael, Howell, Anthony, Buzdar, Aman, Dowsett, Mitch, Forbes, John F., Cuzick, Jack

Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study

- Afentakis, Maria, Dowsett, Mitch, Sestak, Ivana, Salter, Janine, Howell, Tony, Buzdar, Aman, Forbes, John, Cuzick, Jack

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study

- Dowsett, Mitch, Cuzick, Jack, Howell, Anthony, Bugarini, Roberto, Baehner, Frederick L., Shak, Steven, Wale, Christopher, Forbes, John, Mallon, Elizabeth A., Salter, Janine, Quinn, Emma, Dunbier, Anita, Baum, Michael, Buzdar, Aman

Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data

- Cuzick, Jack, Sestak, Ivana, Mershon, John, Mitlak, Bruce H., Powles, Trevor, Veronesi, Umberto, Vogel, Victor, Wickerham, D. Lawrence, Bonanni, Bernardo, Costantino, Joseph P., Cummings, Steve, DeCensi, Andrea, Dowsett, Mitch, Forbes, John F., Ford, Leslie, LaCroix, Andrea Z.

Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer

- Cuzick, Jack, Dowsett, Mitch, Howell, Anthony, Buzdar, Aman U., Forbes, John F., Pineda, Silvia, Wale, Christopher, Salter, Janine, Quinn, Emma, Zabaglo, Lila, Mallon, Elizabeth, Green, Andrew R., Ellis, Ian O.

Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer

- Dowsett, Mitch, Sestak, Ivana, Buus, Richard, Lopez-Knowles, Elena, Mallon, Elizabeth, Howell, Anthony, Forbes, John F., Buzdar, Aman, Cuzick, Jack

Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial

- Cuzick, Jack, Sestak, Ivana, Pinder, Sarah E., Ellis, Ian O., Forsyth, Sharon, Bundred, Nigel J., Forbes, John F., Bishop, Hugh, Fentiman, Ian S., George, William D.

Predictive algorithms for adjuvant therapy: transATAC

- Dowsett, Mitch, Salter, Janine, Zabaglo, Lila, Mallon, Elizabeth, Howell, Antony, Buzdar, Aman U., Forbes, John, Pineda, S., Cuzick, Jack

Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen

- Dowsett, Mitch, Cuzick, Jack, Coombes, Charles, Snowdon, Claire, Gnant, Michael, Jakesz, Raimund, Kaufmann, Manfred, Boccardo, Francesco, Godwin, Jon, Davies, Christina, Peto, Richard, Ingle, Jim, Coates, Alan, Forbes, John, Bliss, Judith, Buyse, Marc, Baum, Michael, Buzdar, Aman, Colleoni, Marco

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

- Cuzick, Jack, Sestak, Ivana, Baum, Michael, Buzdar, Aman, Howell, Anthony, Dowsett, Mitch, Forbes, John F.

Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis

- Sestak, Ivana, Cuzick, Jack, Sapunar, Francisco, Eastell, Richard, Forbes, John F., Bianco, Angelo R., Buzdar, Aman U.

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors

- Tang, Gong, Cuzick, Jack, Costantino, Joseph P., Dowsett, Mitch, Forbes, John F., Crager, Michael, Mamounas, Eleftherios P., Shak, Steven, Wolmark, Norman

Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial

- Sestak, Ivana, Distler, Wolfgang, Forbes, John F., Dowsett, Mitch, Howell, Anthony, Cuzick, Jack

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial

- Dowsett, Mitch, Allred, Craig, Bishop, Hugh, Ellis, Ian, Larsimont, Danis, Sasano, Hironobu, Carder, Pauline, Cussac, Antonio L., Knox, Fiona, Speirs, Valerie, Forbes, John, Buzdar, Aman, Knox, Jill, Quinn, Emma, Salter, Janine, Wale, Chris, Cuzick, Jack, Houghton, Joan, Williams, Norman, Mallon, Elizabeth

Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS I)

- Smith, Samuel, Sestak, Ivana, Howell, Anthony, Forbes, John F., Cuzick, Jack

Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS-I)

- Smith, Samuel George, Sestak, Ivanka, Howell, Anthony, Forbes, John, Cuzick, Jack

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial

- Cuzick, Jack, Sestak, Ivana, Cawthorn, Simon, Hamed, Hisham, Holli, Kaija, Howell, Anthony, Forbes, John F.